The MedicX Fund Limited Allotment of scrip shares to Directors (4289T)

TIDMMXF

RNS Number : 4289T

The MedicX Fund Limited

05 January 2017

Press Release

For immediate release

5 January 2017

MedicX Fund Limited

("MedicX Fund", "the Fund" or "the Company")

Allotment of scrip shares to Directors of the Company

Members of the Company's Board of Directors elected to participate in the Company's scrip dividend scheme in respect of the December 2016 dividend for the quarter ended 30 September 2016, and accordingly acquired ordinary shares of no par value in the Company (the "Shares") as disclosed in the table below. The Shares were sold out of treasury by the Company at the previously advised scrip calculation price of 89.30 pence per share.

 
                   Shares      Total    Percentage 
                   Acquired    Shares     Holding 
                                Held 
 David Staples 
  (Chairman)          1,527    93,210   0.023% 
 Shelagh Mason          511    31,192   0.008% 
 John Hearle            498    30,440   0.008% 
 

The Shares were acquired on 30 December 2016 and rank pari passu with the Company's existing ordinary shares.

The Directors detailed above, who elected to participate in the Company's scrip dividend scheme, did so under an election mandate which remains in place until revoked.

Copies of the documents relating to the Scrip Dividend Alternative are available for inspection through the National Storage Mechanism (http://www.morningstar.co.uk/uk/NSM).

End

For further information please contact:

   MedicX Fund                                                                  [phone] 

David Staples, Chairman

   Octopus Healthcare Group                                               [phone] 

Mike Adams, Chief Executive Officer

   Buchanan                                                                      [phone] 

Charles Ryland/Victoria Hayns

Information on MedicX Fund Limited

MedicX Fund Limited ("MXF", "MedicX Fund", "the Fund" or "the Company", or together with its subsidiaries, the "Group") is the specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom and Ireland, listed on the London Stock Exchange, with a portfolio comprising 152 properties.

The Investment Adviser to the Company is Octopus Healthcare Adviser Ltd, which is part of the Octopus Healthcare group. Octopus Healthcare invests in and develops properties as well as creating partnerships to deliver innovative healthcare buildings to improve the health, wealth and wellbeing of the UK. It currently manages over GBP1 billion of healthcare investments across a number of platforms, with a focus on four core areas: GP surgeries, care homes, retirement housing and private hospitals. Octopus Healthcare is part of the Octopus group, a fast-growing UK fund management business with leading positions in several specialist sectors including healthcare property, energy, property finance and smaller company investing. Octopus manages GBP6 billion of funds for more than 50,000 retail and institutional investors.

Octopus Healthcare Adviser Ltd is authorised and regulated by the Financial Conduct Authority.

The Company's website address is www.medicxfund.com. Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website), nor the contents of any website accessible from hyperlinks within this announcement, are incorporated into, or forms part of, this announcement.

The Company's Legal Entity Identifier is 2138008POF35FTNFCB25.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHDMGGMRKKGNZG

(END) Dow Jones Newswires

January 05, 2017 04:00 ET (09:00 GMT)